Angiotensin I-converting enzyme genotype significantly affects progression of IgA glomerulonephritis in an italian population

• Published in: American journal of kidney diseases Vol. 33; no. 6; p. 1071
• Main Authors: Stratta, P, Canavese, C, Ciccone, G, Barolo, S, Dall'Omo, A M, Fasano, M E, Mazzola, G, Berutti, S, Fop, F, Curtoni, E S, Piccoli, G
• Format: Journal Article
• Language: English
• Published: United States 01.06.1999
• Subjects: Adult; Creatine - blood; Disease Progression; European Continental Ancestry Group - genetics; Female; Genotype; Glomerulonephritis, IGA - genetics; Glomerulonephritis, IGA - physiopathology; Humans; Hypertension - etiology; Italy; Male; Peptidyl-Dipeptidase A - genetics; Polymorphism, Genetic; Proteinuria - etiology; Italy
• ISSN: 1523-6838
• DOI: 10.1016/S0272-6386(99)70144-7

To evaluate the role of angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism in the progression of immunoglobulin A glomerulonephritis (IgA-GN), genotype distribution in 81 biopsy-proven cases of IgA-GN was studied. A logistic regression model showed that the risk for homozygous DD was not significantly elevated in patients with IgA-GN compared with healthy subjects (odds ratio = 1.16; confidence interval [CI], 0.4 to 3.3). However, the 5-year (78% v 90%) and 10-year (52% v 82%) renal survival rates for 47 patients with serum creatine (Cr) levels of 1.5 mg/dL or less at biopsy was significantly less in DD patients (n = 18; chi2 = 5.41; P = 0.02). The hazard ratio (HR) for DD (multivariate analysis from Cox proportional model after adjustment for known factors of progression, such as hypertension [HPT] and proteinuria [PTO]) was 3.07 (CI, 1.1 to 9.4). The HR for heavy PTO was 6.1 (CI, 1.9 to 19). The association of DD genotype with progression was even more striking when patients with other risk factors (heavy proteinuria) were excluded, as shown by DD-related risk in the absence (HR = 3.6; CI, 1.1 to 12) and presence (HR = 2; CI, 0.4 to 10) of PTO. The risk ratio was further increased by the coexistence of DD + PTO (HR = 9.16; CI, 1.8 to 15.7). Furthermore, in a cross-sectional study among patients with IgA-GN, a logistic regression model showed that the risk for homozygous DD was greater, although not at a statistically significant level in the end-stage renal failure subgroup compared with the normal renal function subgroup (odds ratio = 3.16; CI, 0.7 to 13.7) after adjustment by sex, age at biopsy, HPT, PTO, and therapy. Last, DD was significantly more frequent in those patients who started hemodialysis at an earlier age (chi2 for trend = 6.81; P = 0.009). Our study further supports that ACE genotype is a risk factor not for the development, but for the worsening of IgA-GN clinical course. However, on the basis of current knowledge, we cannot exclude that I/D polymorphism may simply serve as a prognostic marker, eventually linked with other discrete loci involved in the progression of renal damage.